Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Proteomics
New proteomics findings from C. Ryppa and co-researchers published
October 9th, 2008
"Integrins, especially integrin alpha(v)beta(3), are attractive receptors for vascular targeting strategies. Recently, a divalent RGD peptidomimetic, E-[c(RGDfK)(2)], has been described that demonstrates increased uptake in human ovarian carcinoma OVCAR-3 xenograft tumors," scientists in Freiburg, Germany report. "Inspired by these results, we set out to develop doxorubicin conjugates with E-[c(RGDfK)(2)] by binding two different maleimide derivatives of doxorubicin to E-[c(RGDfK)(2)] that was thiolated with iminothiolane. In this way, two water-soluble derivatives were obtained, E-[c(RGDfK)(2)]-DOXO-1 and E-[c(RGDfK)(2)]-DOXO-2. In E-[c(RGDfK)(2)]-DOXO-1, doxorubicin...
Source: Women's Health Weekly (2008-10-09)
|
